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Abstract
Background—Despite high two-dose measles-mumps-rubella (MMR) vaccine coverage, a large 
mumps outbreak occurred on the U.S. Territory of Guam during 2009–2010, primarily in school-
aged children.
Methods—We implemented active surveillance in April 2010 during the outbreak peak and 
characterized the outbreak epidemiology. We administered third doses of MMR vaccine to eligible 
students aged 9–14 years in 7 schools with the highest attack rates (ARs) between 5/18/2010—
5/21/2010. Baseline surveys, follow-up surveys, and case-reports were used to determine mumps 
ARs. Adverse events post-vaccination were monitored.
Results—Between 12/1/2009—12/31/2010, 505 mumps cases were reported. Self-reported 
Pohnpeians and Chuukese had the highest relative risks (54.7 and 19.7, respectively) and highest 
crowding indices (mean: 3.1 and 3.0 persons/bedroom, respectively). Among 287 (57%) school-
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aged case-patients, 270 (93%) had ≥2 MMR doses. A third MMR dose was administered to 1068 
(33%) eligible students. Three-dose vaccinated students had an AR of 0.9/1000 compared to 
2.4/1000 among two-dose vaccinated students >1 incubation period post-intervention, but the 
difference was not significant (p= 0.67). No serious adverse events were reported.
Conclusions—This mumps outbreak occurred in a highly vaccinated population. The highest 
ARs occurred in ethnic minority populations with the highest household crowding indices. After 
the third dose MMR intervention in highly affected schools, the AR in three-dose MMR recipients 
was 60% lower than two-dose vaccine recipients, but the difference was not statistically significant 
and the intervention occurred after the outbreak peaked. This outbreak may have persisted due to 
crowding at home and high student contact rates.
Keywords
mumps; outbreak control; third dose MMR intervention; vaccine preventable disease; 
immunization
INTRODUCTION
Mumps is an acute, viral illness that classically manifests with fever and parotitis; 25–40% 
of infections are asymptomatic. Severe complications include encephalitis[1], deafness[2, 3], 
and orchitis[4]. Mumps vaccine was licensed in the United States in 1967 and recommended 
for routine use in 1977. A second dose of measles-mumps-rubella (MMR) vaccine was 
recommended for all school-aged children and select high risk groups in 1989 for measles 
prevention[5]. Due to high two-dose MMR vaccine coverage, rates of reported mumps in the 
U.S. declined by over 99% in 2005 compared with the immediate pre-vaccine era[6]. Annual 
mumps incidence in the U.S. was approximately 1 case per million population (0.9–1.2 per 
million/population) between 2000 and 2005[7]. A mumps elimination goal was set for 
2010[8].
However, from 2006—2010, several large mumps outbreaks occurred in primarily two-dose 
vaccinated U.S. populations. In 2006, 6584 reported cases occurred, mainly affecting 
Midwestern college students. Standard control measures (e.g. isolation and vaccine catch-up 
campaigns) were implemented for outbreak control[6]. During 2009–2010, 3502 mumps 
cases were reported in a highly two-dose vaccinated population in an Orthodox Jewish 
community in the Northeast; this outbreak was the first to use a third dose MMR vaccine 
intervention for outbreak control[9].
On February 25, 2010, Guam Department of Public Health and Social Services (DPHSS) 
was informed of a mumps case in a two-dose vaccinated 15 year old male. More cases were 
subsequently reported, primarily among vaccinated school children aged 9–14 years. The 
last reported mumps outbreak on Guam occurred in 1958; in the past decade, Guam reported 
an average of four mumps cases annually. As part of the public health response to this 
outbreak, a third dose of MMR vaccine was administered. We evaluated the outbreak 
epidemiology and the safety and impact of a third dose MMR vaccine intervention in target 
populations for outbreak control.
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METHODS
Setting
Guam is a U.S. territory with a 2010 population of ~180,692 persons[10]. The primary 
ethnicity on Guam is Chamorro, comprising 37% of the population[10]. Guam follows the 
Advisory Committee on Immunization Practices (ACIP) recommendations for MMR 
vaccination: the first MMR dose is administered at ages 12–15 months and the second dose 
at 4–6 years[11].
Outbreak Epidemiology
Mumps cases were classified according to the 2008 Council of State and Territorial 
Epidemiologists mumps case definition[12]. On Guam, health-care providers are mandated 
by law to report mumps cases to Guam DPHSS. DPHSS instituted active surveillance April 
20, 2010 at the peak of the outbreak with schools, daycares, select provider clinics and 
laboratories reporting mumps cases daily; close contacts of reported cases were investigated. 
DPHSS collected information on demographics, laboratory results, symptom onset date, 
mumps-related complications, and vaccination history. Vaccination status of all case-patients 
was verified by health-care providers; administration dates were noted.
Laboratory criteria for mumps diagnosis included isolation of mumps virus from clinical 
specimens (i.e., either an oropharyngeal or buccal mucosa swab), detection of mumps 
nucleic acid, or detection of mumps IgM antibody measured by qualitative assays. All 
culture, reverse transcription-polymerase chain reaction (RT-PCR) tests[13], mumps virus 
sequencing, and genotype analysis[14, 15] were conducted by the Centers for Disease 
Control and Prevention (CDC). IgM tests were conducted at CDC and state and commercial 
labs.
The outbreak period was defined as 12/1/2009—12/31/2010. We calculated mumps ARs for 
the population overall and by sex, age, and ethnicity. AR denominators were obtained from 
the projected 2010 Guam census data[10]. Because census age groupings did not correlate 
with the age group most affected by the outbreak, we created a 9–14 year age group category 
by adding one-fifth of the 5–9 year census age group to the 10–14 year census age group.
Third Dose MMR Vaccine Intervention
Public schools were eligible for the third dose intervention if they had >90% two-dose MMR 
vaccine coverage, ongoing mumps transmission (i.e., mumps cases in the preceding two 
weeks), and a mumps AR of >5/1000. Students in the intervention schools were eligible if 
they were in the age group with the highest AR (aged 9–14 years), had a history of two 
MMR vaccine doses, had not previously received a third MMR vaccine dose, and had no 
history of mumps. Students who were not up-to-date with the recommended two doses of 
MMR vaccine were offered appropriate vaccinations. School vaccination coverage was 
assessed by reviewing school vaccine records.
Vaccination status of students participating in the study was confirmed either through 
immunization card review by parents or immunization staff, or review of DPHSS and school 
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vaccine registries. For students with unknown or incomplete vaccination status, verification 
was obtained from health-care providers.
This study was approved by the CDC and Guam Memorial Hospital Institutional Review 
Boards. Written informed parental consent and student assent were obtained.
Baseline and follow-up surveys captured demographic characteristics, vaccination history, 
mumps history, clinical features and complications of mumps, number of people in the 
household, and number of bedrooms in the house. Follow-up surveys also captured possible 
adverse events following immunization. Baseline surveys were distributed to all eligible 
students during the third dose MMR vaccine intervention from May 18–21, 2010. Follow-up 
surveys were distributed from October 4–15, 2010 to the original eligible cohort.
Mumps cases were identified by parental report on baseline and follow-up surveys. To 
ensure completeness in ascertaining cases, we supplemented our survey case count with 
confirmed cases reported to Guam DPHSS. If students were not reported as a case to 
DPHSS, did not report mumps in the baseline survey, and did not return a follow-up survey, 
they were categorized as non-cases in our analysis.
Using the exact date of the vaccination clinic at the case-students’ school, we compared 
mumps attack rates (ARs) following the intervention between eligible students aged 9–14 
years who received the third MMR vaccine dose with non-recipients (i.e., students with 
documentation of 2 doses of MMR vaccine) from post-intervention day 22 through day 228 
(i.e., December 31, 2010, the end of the study period). We excluded the 21 days (1 
incubation period) following the intervention from the analysis (May 22– June 11, 2010) 
since persons infected prior or during the intervention may have been incubating mumps 
during this timeframe[16, 17].
All vaccine recipients were monitored 30 minutes post-intervention to evaluate immediate 
adverse events. The follow-up survey contained questions on adverse events that may have 
occurred up to two weeks post-intervention, including any serious adverse events resulting 
in permanent disability, hospitalization, life-threatening illnesses, or death[18].
All data were analyzed with SAS 9.2 (Cary, NC). Denominators for school ARs were 
calculated using school enrollment data. We compared post-intervention mumps ARs 
between students who received the third dose of MMR vaccine with those who did not using 
a Fischer’s Exact test. P-values of <0.05 were considered significant. Relative risks (RR) and 
95% confidence intervals (CI) were calculated. Crowding was assessed by dividing the 
number of household members by bedrooms in the house. Two-independent samples t-tests 
were used to compare differences between the means for household size and crowding 
between ethnic groups.
RESULTS
Outbreak Epidemiology
The first case of mumps was reported to DPHSS on February 25, 2010, but the index case-
patient was retrospectively identified as having parotitis onset December 7, 2009. The index 
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case-patient was a Guam resident who imported mumps from the island of Pohnpei where 
mumps was known to be circulating. Between 12/1/2009—12/31/2010, 505 cases of mumps 
were reported (Figure 1) with a median age of 12 years (range: 2 months to 79 years) [Table 
1]; 50% were males. There were 5 (3.3%) reports of orchitis among post-pubertal males 
with three additional reports of orchitis among pre-pubertal males aged 3, 7, and 9 years. 
There were 2 hospitalizations for mumps-related illness; one was for supportive care of 
orchitis and the other was misdiagnosed as neck cellulitis but was later confirmed as mumps 
parotitis. No deaths were reported.
Children aged 9–14 years had the highest overall AR (8.4/1000), followed by those aged 5–8 
years (5.3/1000), 15–19 years (3.9/1000), and 0–4 years (3.7/1000). Adults 40 years and 
older had the lowest AR (0.5/1000). Correspondingly, all age groups less than 40 years were 
statistically more likely to have reported mumps case-patients than adults 40 years or older, 
and children aged 9–14 years had a 16 times higher risk (RR=16.3, CI: 11.2–23.5). 
Compared to persons self-reporting “other” ethnicity, which comprised 32% of the Guam 
population, persons who reported their ethnicity as Pohnpeian or Chuukese had a markedly 
elevated risk of mumps [Pohnpeian (RR=54.7, CI: 39.2–76.3) or Chuukese (RR=19.7, CI: 
14.5–26.9)]. In contrast, persons reporting Filipino ethnicity did not have an elevated risk 
and those reporting Chamorro ethnicity had a mildly elevated risk (Table 1). Ninety-six 
percent of mumps case-patients aged 9–14 years were vaccinated with two doses of MMR 
vaccine, followed by 90% of case-patients aged 5–8 years, and 88% of case-patients aged 
15–19 years (Table 2).
Laboratory
Of 505 case-patients, 309 (61%) had sera tested for mumps IgM; 60 (19%) tested IgM 
positive. Twenty-eight (82%) of 34 viral specimens tested positive by RT-PCR, of which 14 
(41%) also tested positive by culture1. Sequence analysis of mumps viruses identified 
mumps genotype G as the outbreak strain.
Intervention Schools
There are 64 public and private schools on Guam (preschool through high school). Seven 
(11%) schools (four elementary and three middle schools) met the inclusion criteria with 
ARs ranging from 8.4–31.5/1000 among children aged 9–14 years (i.e., grades 4–8). These 
seven schools were in the north and central regions of Guam, the most densely populated 
part of the island. The high mumps ARs of these seven schools reflected the distribution of 
cases on Guam, as a majority of the island’s case-patients occurred in this age group and 
resided in the north and central regions. All seven schools had two-dose MMR vaccine 
coverage between 99%–100%.
1The difference in positive results between RT-PCR and culture is likely because two of the three shipments of specimens were not 
frozen on arrival compromising specimen quality. In the only shipment that arrived frozen, 11 of 14 specimens were positive by 
culture.
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MMR Vaccine Third Dose Intervention
The third dose intervention was implemented in the highest AR schools in the most affected 
age group (students aged 9–14 years), but occurred after the outbreak peaked (Figure 3a); 
186 (37%) of the 505 outbreak cases occurred after the intervention. There were 3364 
students in grades 4–8 in the seven selected schools, of whom 3239 were eligible for the 
third dose intervention. Of those eligible, 1068 (33%) received a third dose of MMR 
vaccine. At least one survey was returned by 2434 (75%) eligible students, with 1236 (38%) 
returning a baseline and 2032 (63%) returning a follow-up survey. All 1068 vaccinees 
returned a baseline survey and 734 (69%) returned a follow-up survey (Figure 2). Non-
respondents were statistically more likely to be male (p=0.0024) and in grades 7–8 
(p<0.0001) compared to survey respondents. Despite differences between survey 
respondents and non-respondents, respondents reported similar demographic characteristics 
proportionally compared to the Guam general population with 1220 (50%) males, 1006 
(41%) self-reporting Chamorro ethnicity, and 1761 (77%) responding they had insurance. 
Students who received the third dose were statistically more likely to be without health 
insurance (p=0.008), female, (p<0.0001), and in grades 4–6 (p=0.0002), compared with non-
vaccine recipients.
The mean household size among respondents was 6.2 members (range: 2–26). Chuukese 
respondents had the largest household size with a mean of 7.3 members (range: 2–26), 
followed by Pohnpeian respondents with a mean of 7.0 members (range: 2–17), Chamorro 
respondents with a mean of 6.2 members (range: 2–18), and Filipino respondents with mean 
of 5.7 members (ranges: 2–16). The mean number of household members among Chuukese 
and Pohnpeian respondents was significantly higher than among Chamorro and Filipino 
respondents (p<0.05).
The average crowding index among respondents was 2.3 persons per bedroom. Pohnpeian 
and Chuukese households had the highest crowding indices with a mean of 3.1 and 3.0 
persons per bedroom (ranges: 1–10 and 1–13, respectively), compared with Chamorro and 
Filipino households which had crowding indices of 2.2 and 2.1 persons per bedroom 
(ranges: 0.3–14 and 0.7–14, respectively). The mean crowding index in Pohnpeian and 
Chuukese households was significantly higher than in Chamorro and Filipino households 
(p<0.0001).
Six students eligible for the third MMR dose from 4 different intervention schools were 
diagnosed with mumps in the post-intervention period; 5 (83%) did not receive the third 
MMR dose and 1 (17%) received the third MMR dose (Table 3). The mumps AR was 2.6-
fold lower in those who received the third MMR dose compared with two-dose recipients 
(0.9/1000 versus 2.3/1000, RR= 0.4; CI: 0.05–3.5, p=0.67); this difference was not 
statistically significant (Figure 3b).
Adverse Events
No immediate adverse events were reported. During the two weeks post-vaccination, 32 
(6.0%) students reported an adverse event; the most frequent self-reported events were: joint 
aches (2.6%), pain, redness and swelling at the injection site (2.4%), and dizziness (2.4%) 
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[Table 4]. No serious adverse events were reported, and no medical attention was sought 
related to these events.
DISCUSSION
The Guam mumps outbreak was the third largest in the U.S. and its territories since 2005, 
and the second outbreak where a third dose of MMR vaccine was administered, thus 
providing an opportunity to evaluate the impact and safety of a third dose MMR vaccine 
intervention in mumps outbreak control. Although the intervention occurred after the 
outbreak peaked, the AR in students who received the third dose of MMR vaccine was 60% 
lower than two-dose vaccine recipients during the post-intervention period. Perhaps due to 
the smaller number of mumps cases that occurred at this stage of the outbreak, the difference 
in ARs was not statistically significant. Nonetheless, the effect of a third dose in boosting 
immunity and increasing vaccine effectiveness is biologically plausible; rapid anamnestic 
antibody responses following third MMR vaccine doses have been reported[19].
Mumps outbreaks have occurred in other populations with high two-dose vaccination 
coverage, including tradition-observant Orthodox Jewish adolescent school students[9], 
Midwestern college-age students[6], and international settings[20–22]. Some of the potential 
contributors in those outbreaks, including high population density and high contact rates, 
may also have contributed to the outbreak in Guam[6]. Guam families typically live in 
crowded environments with large extended families (i.e., Guam has a crowding index of 3.9 
persons/household compared with 2.6 persons/household on the U.S. mainland; survey 
respondents had an average of 6.2 family members[10]). Due to high contact rates among 
students, the importance of schools as high-risk transmission settings for mumps and other 
outbreaks of vaccine-preventable diseases has been well-documented[6, 23].
Compared with other two-dose mumps outbreaks, some epidemiological features of this 
outbreak were unusual. Children aged 9–14 years were disproportionately affected; this was 
a younger age group than described in similar outbreaks[6, 9]. Cases occurred in all ethnic 
groups, but the highest ARs occurred in the ethnic minority populations with the most 
household members and highest household crowding indices. We are unable to explain this 
epidemiological finding but postulate that contributing factors may include higher household 
density and/or genetic effects.
Though this outbreak occurred in a highly-vaccinated population, there were lower 
transmission rates and fewer mumps-related complications than would be expected in the 
absence of appropriate vaccination. Orchitis was reported among 3.3% of post-pubertal 
males. This is consistent with lower rates of complications in fully vaccinated persons and 
with findings from the Northeast outbreak[9], but much less than pre-vaccine rates of 30% 
(range 19–44%) though the younger median age of post-pubertal cases in this outbreak 
should be considered when interpreting this comparison[24–28]. The occurrence of 3 reports 
of orchitis in pre-pubertal males was unusual since there have only been 12 previously 
documented reports of pre-pubertal mumps orchitis[29, 30]. However, 2 of the 3 cases were 
reported by parents, and the third patient was hospitalized for orchitis with no documented 
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parotitis or laboratory confirmation. Previous studies have documented that mumps can 
present as orchitis in the absence of parotitis[24, 31].
Genotype G, the outbreak strain, was identified in the 2006 and 2009–2010 outbreaks in the 
U.S., the outbreak in Canada in 2005–2006, the United Kingdom in 2004–2005, and is seen 
globally, though this lineage was different from the Northeast outbreak. Mumps is endemic 
throughout the world; only 61% of countries vaccinate against mumps[32]. It is possible that 
since the last reported mumps outbreak on Guam in 1958 and prior to this outbreak, mumps 
cases were imported on the island from international visitors but went undetected. 
Nonetheless, although over one million international passengers visit Guam annually[33], 
the index case-patient was a Guam resident who traveled to another Pacific island where 
mumps was known to be circulating.
MMR vaccine in the U.S. contains the Jeryl-Lynn mumps strain[5, 11]. In post-licensure 
studies, vaccine effectiveness against clinical mumps has a median effectiveness of 78% 
(range: 49%–92%) for one dose of mumps vaccine and 88% (range: 66%–95%) for two 
doses of mumps vaccine[6, 34, 35]. Thus, although reported mumps cases in the U.S. were 
99% lower in 2010 compared with the pre-vaccine era, sustained transmission of mumps in 
highly vaccinated two dose populations occurs in rare circumstances[6, 9]. We were unable 
to evaluate two-dose vaccine effectiveness during the outbreak in Guam due to the extremely 
high two dose coverage. Effectiveness of three doses of mumps vaccine has not been 
evaluated.
Our findings are subject to limitations. Many families did not visit a health-care provider for 
subsequent ill family members, likely leading to underreporting. There were anecdotal 
reports from community leaders that there were large numbers of unreported cases despite 
active surveillance. Although transmission was still occurring, the intervention occurred 
after the outbreak peaked. The small numbers of mumps cases in the targeted population 
post-intervention limited our ability to draw firm conclusions about the impact of the third 
dose intervention. There were statistically significant differences between survey 
respondents and non-respondents, as well as among survey participants who received the 
third dose of MMR vaccine and those who did not. However, these differences are unlikely 
to bias the effect of a third dose of MMR vaccine. Census data were not available to explore 
crowding indices by ethnicity among the Guam general population.
Implementing the third dose intervention in the school setting allowed us to verify 
vaccination records while targeting specific age groups in the most highly affected regions. 
However, the third dose was only administered to 5.3% of all students aged 9–14 years 
making it difficult to draw conclusions about the impact of the intervention at the 
population-level.
Mumps outbreaks can cause a substantial economic and resource burden on affected families 
and the public health sector[36], and targeted interventions may be a useful public health 
approach in select high-risk transmission settings. The results of our study suggest that the 
administration of a third dose of MMR vaccine may be an effective method of controlling 
mumps outbreaks in two-dose vaccinated populations in specific settings. For future mumps 
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outbreaks in primarily two-dose vaccinated populations, the focus should be on ensuring that 
everyone is up-to-date with the recommended two-dose vaccination schedule, as well as 
enforcing isolation measures and encouraging appropriate hygiene practices. Our findings 
support the need for additional evaluations that use third doses of MMR vaccine for mumps 
outbreak control in highly two-dose vaccinated populations and underscore the importance 
of initiating the intervention early in the outbreak.
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Key points:
In Guam, a mumps outbreak occurred in highly vaccinated children aged 9–14 years. 
Following a third dose measles-mumps-rubella (MMR) vaccine intervention, the attack 
rate in three-dose recipients was 60% lower than two-dose recipients and no serious 
adverse events were reported.
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Figure 1: 
Epidemiologic curve of reported mumps cases on Guam from December 1, 2009— 
December 31, 2010 1Source: Case Reports, Guam, through December 31, 2010 2 DPHSS, 
Department of Public Health and Social Services
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Figure 2: 
Flow sheet of students eligible for participation in the third dose MMR vaccine intervention 
and surveys, Guam 2010
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Figure 3a: 
Mumps attack rates (cases/1000) by age group by two-week period, Guam, December 1, 
2009— December 31, 2010
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Figure 3b: 
Comparison of mumps attack rates (cases/1000) post-intervention among eligible students 
who received the third MMR vaccine dose compared with those who did not receive the 
third dose, Guam, December 1, 2009— December 31, 2010 * >1 incubation period post-
intervention
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Table 1.
Demographic Characteristics of Mumps Case-patients (n=505) Compared with the Guam General Population 
(n=180,692), Guam, December 1, 2009— December 31, 2010
Demographics Cases (n=505)
Guam Census
(n=180,692)
Attack Rates
(per 1000)
Risk Ratio
(Confidence
Interval)
Gender
Male 251 (50) 91820 (51) 2.7 0.96 (0.80–1.14)
Female 254 (50) 88872 (49) 2.9 Ref
Age Group (years)
0–4 60 (12) 16035 (9) 3.7 7.3 (4.7–11.1)
5–8 70 (14) 13260 (7) 5.3 10.2 (6.8–15.5)
9–14 169 (34) 20134 (11) 8.4 16.2 (11.2–23.5)
15–19 68 (13) 16066 (9) 3.9 8.2 (5.4–12.4)
20–29 54 (11) 26560 (15) 2.0 3.9 (2.6–6.1)
30–39 51 (10) 24455 (14) 2.1 4.0 (2.6–6.3)
40+ 33 (7) 64182 (36) 0.5 Ref
Ethnicity
Chamorro 170 (34) 66879 (37) 2.5 2.6 (2.0–3.6)
Chuukese 140 (28) 7271 (4) 19.3 19.7 (14.5–26.9)
Filipino 52 (10) 47540 (26) 1.1 1.1 (0.8–1.7)
Pohnpeian 88 (17) 1594 (1) 55.2 54.7 (39.2–76.3)
Other 55 (11) 57408 (32) 1.0 Ref
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Table 2.
Vaccination Status by Age Group of Mumps Case-patients, Guam, December 1, 2009— December 31, 2010
Age group Vaccinated
with 1 MMR
dose
(percent)
Vaccinated
with 2 MMR
doses
(percent)
Unvaccinated
(percent)
Total case-patients
<1 year 0 (0) 0 (0) 5 (100) 5
1–4 years 33 (60.0) 4 (7.3) 18 (32.7) 55
5–8 years 2 (2.9) 63 (90.0) 5 (7.1) 70
9–14 years 5 (3.0) 162 (95.8) 2 (1.2) 169
15–19 years 1 (1.5) 60 (88.2) 7 (10.3) 68
20–29 years 3 (5.6) 10 (18.5) 41 (75.9) 54
30–39 years 8 (15.7) 4 (7.8) 39 (76.5) 51
≥40 years 1 (3.0) 2 (6.1) 30 (90.9) 33
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Table 3.
Mumps Attack Rates among Students Aged 9–14 Years in Seven Schools More Than One Incubation Period 
following the Third Dose MMR Vaccine Intervention, Guam 2010
>1 incubation period post-
vaccination
Comparison of attack rates
between students with 3 versus 2
MMR doses >1 incubation period
post-vaccination¶
Number of
Cases N
Attack Rates
(per 1000)
Relative Risk
(95% Confidence
Intervals) P-value
Students who had 2 doses of MMR vaccine 5 2171 2.3 Reference
Students who had 3 doses of MMR vaccine 1 1068 0.9 0.4 (0.05,3.5) 0.67
¶
value calculated using Fischer’s exact test
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Table 4.
Self-reported Adverse Events Reported during the Two Weeks following the Third Dose MMR Vaccine 
Intervention (N=533)*, Guam, 2010
Adverse Event Number (%)
Joint ache (n=506) 13 (2.6)
Pain/redness (n=509) 12 (2.4)
Dizzy (n=509) 12 (2.4)
Fever (n=512) 5 (1.0)
Syncope (n=508) 0 (0)
Difficulty breathing (n=509) 0 (0)
Hives/rash on the body (n=508) 0 (0)
Sought medical care following third dose of MMR vaccine (n=487) 0 (0)
Any adverse event (n=533)** 32 (6.0)
*Not all vaccinees completed this section of the survey.
**8 respondents reported 2 adverse events, and 1 respondent reported 3 adverse events
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